Site icon pharmaceutical daily

Schrödinger to Participate in Five Upcoming Investor Conferences

NEW YORK–(BUSINESS WIRE)–Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will participate virtually at the following investor conferences:

Additionally, the company will participate in one-on-one meetings during the Berenberg Discover AI Seminar 2021 on Wednesday, December 1st.

The live and pre-recorded webcasts can be accessed under “News & Events” in the investors section of Schrödinger’s website, https://ir.schrodinger.com/news-and-events/event-calendar and will be archived for approximately seven days.

About Schrödinger

Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

Founded in 1990, Schrödinger has over 500 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, our blog www.extrapolations.com, or follow us on LinkedIn and Twitter.

Contacts

Jaren Irene Madden

Schrödinger, Inc.

jaren.madden@schrodinger.com
617-286-6264

Tracy Lessor

Schrödinger, Inc.

tracy.lessor@schrodinger.com
617-519-9827

Exit mobile version